New top line data has emerged from the company’s phase 1b study evaluating potential for treating sepsis
News
UK atrial fibrillation research incorporates Brainomix
Research will analyse how Huawei’s wearable technology detects atrial fibrillation in post-stroke patients
CSL’s first gene therapy for haemophilia B approved
Boost for effected patients as HEMGENIX receives green light from European Commission
Trio of COVID-19 treatments receive NICE nod
Final draft guidance from NICE ensures people at highest risk will have access to COVID-19 therapies
Important milestone for Valneva’s chikungunya vaccine
VLA1553 is a single-dose, live-attenuated vaccine candidate targeting the highly dangerous chikungunya virus
Janssen reveals vital niraparib data
Research concerns the effect of niraparib when combined with abiraterone acetate plus prednisone
Pfizer update Lyme disease vaccine candidate
Research concerning candidate VLA15 has been discontinued across certain trial sites
BGF investment for early-stage businesses
Company has reported strong momentum among the early-stage businesses it invested in last year
AstraZeneca’s Evusheld not recommended for certain adults
Advice concerns the use of COVID-19 vaccine when treating specific vulnerable individuals
Small Pharma begins phase 1 mental health therapy trial
First subject dosed with company’s SPL028 – a proprietary deuterated DMT candidate
National Cancer Institute and Gritstone bio team up on vaccine
Neoantigen vaccine candidate, SLATE-KRAS has demonstrated early evidence of efficacy
Mainz Biomed explores markets in UK and Spain for ColoAlert
Market in Spain is around 26 million patients while the greater London area stands at nine million
Enrolment concluded for Valneva’s chikungunya vaccine
Phase 3 trial of single-shot chikungunya vaccine candidate unfolds among an adolescent cohort
Positive results for Ipsen’s Cabometyx in combination with nivolumab
Benefits were identified with Cabometyx in combination with nivolumab across all efficacy measures
NHS to receive further COVID-19 vaccines from RMI
Collaboration continues to be focused on reaching locations where temporary clinics cannot be easily set up
